Featured Research

from universities, journals, and other organizations

Researchers cut years from drug development with nanoscopic bead technology

Date:
July 16, 2010
Source:
Wake Forest University
Summary:
New research confirms that a revolutionary technology will slash years off the time it takes to develop drugs -- bringing vital new treatments to patients much more quickly. Lab-on-Bead uses tiny beads studded with "pins" that match a drug to a disease marker in a single step, so researchers can test an infinite number of possibilities for treatments all at once. When Lab-on-Bead makes a match, it has found a viable treatment for a specific disease -- speeding up drug discovery by as much as 10,000 times and cutting out years of testing and re-testing in the laboratory.

New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs -- bringing vital new treatments to patients much more quickly.

Lab-on-Bead uses tiny beads studded with "pins" that match a drug to a disease marker in a single step, so researchers can test an infinite number of possibilities for treatments all at once. When Lab-on-Bead makes a match, it has found a viable treatment for a specific disease -- speeding up drug discovery by as much as 10,000 times and cutting out years of testing and re-testing in the laboratory.

"It helps the most interesting new drugs work together to stick their heads up above the crowd," said Jed C. Macosko, Ph.D., an associate professor of Physics at Wake Forest and primary inventor of the Lab-on-Bead technology. "Each type of drug has its own molecular barcode. Then, with the help of matching DNA barcodes on each nanoscopic bead, all the drugs of a certain type find their own 'home' bead and work together to make themselves known in our drug discovery process. It's kind of like when Dr. Seuss's Whos down in Whoville all yelled together so that Horton the elephant and all of his friends could hear them."

Macosko and Martin Guthold, Ph.D., an associate professor of physics at Wake Forest and the co-inventor of Lab-on-Bead, will work with the biotechnology startup NanoMedica Inc. to test how drug companies will use the new tool. The company has relocated to Winston-Salem from New Jersey; Macosko serves as the company's chief innovation officer and Guthold is its chief science officer. The company has one year to work with the technology to bring it to market or relinquish the rights to the

Lab-on-Bead screens millions of chemicals simultaneously using plastic beads so small that 1,000 of them would fit across a human hair. Pharmaceutical companies would use the technology to identify treatments and diagnostics for conditions ranging from cancer to Alzheimer's.

One of the targets the research team has focused on is a breast cancer cell called HER2.

"We want to find a molecule that detects that cancer cell," Guthold said. "In that circumstance, you could use Lab-on-Bead as a diagnostic tool."

The North Carolina Biotechnology Center, a private, nonprofit corporation funded by the N.C. General Assembly, provided $75,000 in funding for the project. Harvard University in Boston and Universit้ de Strasbourg in Strasbourg, France, are providing the chemicals being screened in the Lab-on-Bead process.

"There are an infinite number of possibilities for combining carbon, nitrogen, hydrogen and other elements into different shapes that interact differently in the cells," Macosko said. "Those shapes could block cancer -- they could block all kinds of things.

"If there's some cure to a disease or way to diagnose it, we're going to find it faster."

The Journal of Molecular Recognition is the peer-reviewed publication of the International Society of Molecular Recognition. The Lab-on-Bead study will be in the September/October issue; it appears online in advance of publication. Co-authors of the study include Natalie R. Gassman, J. Patrick Nelli, Samrat Dutta, Adam Kuhn and Keith Bonin, all of Wake Forest; and Zbigniew Pianowski and Nicolas Winssinger, of Universit้ de Strasbourg.


Story Source:

The above story is based on materials provided by Wake Forest University. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University. "Researchers cut years from drug development with nanoscopic bead technology." ScienceDaily. ScienceDaily, 16 July 2010. <www.sciencedaily.com/releases/2010/07/100715123412.htm>.
Wake Forest University. (2010, July 16). Researchers cut years from drug development with nanoscopic bead technology. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/07/100715123412.htm
Wake Forest University. "Researchers cut years from drug development with nanoscopic bead technology." ScienceDaily. www.sciencedaily.com/releases/2010/07/100715123412.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins